Publisher
Springer Science and Business Media LLC
Reference8 articles.
1. KDIGO 2017 Clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl (2011) 7: 1–59, https://doi.org/10.1016/j.kisu.2017.04.001 (2017)
2. Santao Ou LX (2022) A review of the diagnosis and research progress of renal bone disease. Med J West China 34:157–160+167
3. Žilinská Z, Dedinská I, Breza J, Laca L (2017) Effect of paricalcitol on bone density after kidney transplantation: analysis of 2 transplant centers. Iran J Kidney Dis 11:461–466
4. Yolbaş S et al (2018) Paricalcitol inhibits the Wnt/beta-catenin signaling pathway and ameliorates experimentally induced arthritis. Turk J Med Sci 48:1080–1086. https://doi.org/10.3906/sag-1804-62
5. Qu Y, Wu Y, Jiang H (2021) Research progress in the pharmacological actions of the multiple effects and selectivity of the vitamin D analogue paricalcitol: a narrative review. Ann Palliat Med 10: 11177–11190, https://doi.org/10.21037/apm-21-2249